

Pre-Program Activities	Pre-Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Pre-Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
7:30 am	Registration and View Exhibits
8:00 am	Opening Comments and Pre-Test
8:20 am	Review of Viral Hepatitis – HAV, HCV • Highlight of Pre-Lecture 1 • Screening and Treatment of HCV Clinical Cases and Discussion
9:00 am	Hepatitis B: Epidemiology, Natural History and Testing • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • Anti-viral therapies of HBV • The growing relationship between HBV and HDV
9:30 am	Possible Industry Presentation, Break, and View exhibits
10:10 am	 Delta Hepatitis and Hepatitis E Update Worldwide perspective and promising research studies Real world outcome studies on HDV and HEV
10:45 am	 End Stage Liver Disease: Recap and Clinical Cases A review of Pre-course lecture on end-stage liver disease Clinical cases to illustrate HE and Thrombocytopenia
11:15 am	Hepatocellular Carcinoma (HCC) • Screening diagnostic serum assays and imaging tests • Treatment and management options: Ablation, TACE and Surgery
11:45 am	Hepatocellular Carcinoma: New Systemic Treatment Options • A case-based approach to HCC treatment • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC
12:15 pm	Luncheon and Industry Presentation
1:00pm	Dessert and View Exhibits
1:10 pm	 Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis (PSC) Epidemiology of PSC and Ursodiol and Antibiotic Treatments Predicting outcomes and Improving Survival in PSC patients Causes and Markers of PBC Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
1:50 pm	 Alcohol Associated Liver Disease The growing prevalence of alcohol over-consumption and its impact on liver health Warning signs and intervention in alcohol-associated hepatitis
2:20 pm	Fluid Management, Ascites and Hepatorenal Syndrome The diagnosis and treatment of ascites How cirrhosis can lead to portal hypertension, ascites, kidney disease and hepatorenal syndrome New and emerging treatment approaches for of HRS
2:50 pm	Break & View Exhibits
3:00 pm	NAFLD and NASH



2023 Prevention & Therapies for Hepatitis and Chronic Liver Disease

Seminar Agenda

	3:30 pm	 NASH Treatments in Practice and in Development Current therapies for NASH including Updates from AASLD and EASL Lifestyle changes as a therapy Drugs in clinical development for NASH
	4:15 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:30 pm
I	Post-program activities	Lecture 3 - SARS-CoV-2 and its Effect on the Liver – 45 minutes Lecture 4 - Overcoming barriers to liver health in special populations - 45 minutes

Course Directors: Paul J. Pockros, MD - Scripps Clinic

Peer Review: Tracy Ander, DO - University of Louisville School of Medicine